Acecainide hydrochloride (BioDeep_00000783020)

   


代谢物信息卡片


N-AcetylprocainaMide hydrochloride

化学式: C15H24ClN3O2 (313.15569539999996)
中文名称: N-乙酰普鲁卡因胺 盐酸盐
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C.Cl
InChI: 1H

描述信息

C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
C93038 - Cation Channel Blocker

同义名列表

2 个代谢物同义名

N-AcetylprocainaMide hydrochloride; Acecainide hydrochloride



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Ahmed N Mohamed, Ahmed M Abdelhady, Dustin Spencer, Kevin M Sowinski, James E Tisdale, Brian R Overholser. Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013 Jun; 61(6):1046-8. doi: 10.1053/j.ajkd.2013.02.358. [PMID: 23562328]
  • Amitava Dasgupta, Melissa Hovanetz, Margaret Olsen, Alice Wells, Jeffrey K Actor. Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice. Archives of pathology & laboratory medicine. 2007 Jul; 131(7):1094-8. doi: 10.5858/2007-131-1094-dieosj. [PMID: 17616997]
  • F A Brightman, D E Leahy, G E Searle, S Thomas. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug metabolism and disposition: the biological fate of chemicals. 2006 Jan; 34(1):94-101. doi: 10.1124/dmd.105.004838. [PMID: 16221756]
  • Larry A Bauer, Douglas J Black, Jennifer S Lill, Julie Garrison, Vidmantas A Raisys, Thomas M Hooton. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances. Antimicrobial agents and chemotherapy. 2005 Apr; 49(4):1649-51. doi: 10.1128/aac.49.4.1649-1651.2005. [PMID: 15793163]
  • Jimmy Flarakos, Kenneth L Morand, Paul Vouros. High-throughput solution-based medicinal library screening against human serum albumin. Analytical chemistry. 2005 Mar; 77(5):1345-53. doi: 10.1021/ac048685z. [PMID: 15732917]
  • Y L He, N Kitada, M Yasuhara, R Hori. Quantitative estimation of renal clearance of N-acetylprocainamide in rats with various experimental acute renal failure. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2001 Jun; 13(3):303-8. doi: 10.1016/s0928-0987(01)00117-8. [PMID: 11384853]
  • T Nakahara, H Moriuchi, Y Tanaka, M Yunoki, Y Kubota, K Sakamato, K Shigenobu, K Ishii. Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle. European journal of pharmacology. 2001 Mar; 415(1):73-8. doi: 10.1016/s0014-2999(01)00796-8. [PMID: 11245854]
  • N D Eddington, F Adekoya, J Kharidia. The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide. Biopharmaceutics & drug disposition. 1998 Jul; 19(5):291-6. doi: 10.1002/(sici)1099-081x(199807)19:5<291::aid-bdd106>3.0.co;2-x. [PMID: 9673780]
  • E Lessard, A Fortin, A Coquet, P M Bélanger, B A Hamelin, J Turgeon. Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study. Journal of chromatographic science. 1998 Jan; 36(1):49-54. doi: 10.1093/chromsci/36.1.49. [PMID: 9443381]
  • G Vargas, J Havel, E Hadasová. Direct determination of procainamide and N-acetylprocainamide by capillary zone electrophoresis in pharmaceutical formulations and urine. Journal of chromatography. A. 1997 Jun; 772(1-2):271-6. doi: 10.1016/s0021-9673(97)00106-4. [PMID: 9226929]
  • K Okumura, T Kita, S Chikazawa, F Komada, S Iwakawa, Y Tanigawara. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clinical pharmacology and therapeutics. 1997 May; 61(5):509-17. doi: 10.1016/s0009-9236(97)90131-4. [PMID: 9164413]
  • J E Tisdale, I D Padhi, J A Ware, C K Svensson. Comparison of fluorescence polarization immunoassay with liquid chromatography for quantification of procainamide and N-acetylprocainamide in urine. Therapeutic drug monitoring. 1996 Dec; 18(6):693-7. doi: 10.1097/00007691-199612000-00011. [PMID: 8946667]
  • B B Yang, R B Abel, A C Uprichard, J A Smithers, S T Forgue. Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization. Journal of clinical pharmacology. 1996 Jul; 36(7):623-33. doi: 10.1002/j.1552-4604.1996.tb04227.x. [PMID: 8844445]
  • J E Tisdale, M I Rudis, I D Padhi, C K Svensson, C R Webb, S Borzak, J A Ware, A Krepostman, B J Zarowitz. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. Journal of clinical pharmacology. 1995 Sep; 35(9):902-10. doi: 10.1002/j.1552-4604.1995.tb04135.x. [PMID: 8786250]
  • E J Ellis, W R Ravis, M Malloy, S H Duran, B G Smyth. The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. Journal of veterinary pharmacology and therapeutics. 1994 Aug; 17(4):265-70. doi: 10.1111/j.1365-2885.1994.tb00243.x. [PMID: 7525982]
  • C D Miller, M A Oleshansky, K F Gibson, L R Cantilena. Procainamide-induced myasthenia-like weakness and dysphagia. Therapeutic drug monitoring. 1993 Jun; 15(3):251-4. doi: 10.1097/00007691-199306000-00013. [PMID: 7687390]
  • B Gawrońska-Szklarz, W Górnik, J Kutrzeba, J Wójcicki, J Zakrzewski. [Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype]. Polski tygodnik lekarski (Warsaw, Poland : 1960). 1992 Oct; 47(40-41):921-3. doi: NULL. [PMID: 1284448]
  • P M Kar, K Kellner, T S Ing, D J Leehey. Combined high-efficiency hemodialysis and charcoal hemoperfusion in severe N-acetylprocainamide intoxication. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1992 Oct; 20(4):403-6. doi: 10.1016/s0272-6386(12)70307-4. [PMID: 1384320]
  • X D Liu, N Deng, S K Huang. Prediction of N-acetylprocainamide disposition kinetics in rat by combination of gamma variate and physiological pharmacokinetic model. Zhongguo yao li xue bao = Acta pharmacologica Sinica. 1992 Mar; 13(2):97-103. doi: NULL. [PMID: 1376015]
  • C A Carnes, J D Coyle. Evaluation of very rapid emit Qst methods for measuring serum procainamide and N-acetylprocainamide concentrations. Pharmacotherapy. 1992; 12(1):40-4. doi: NULL. [PMID: 1372425]
  • T L Dise, A Stolfi, C W Clarkson, A S Pickoff. Rate-dependent effects of lidocaine on His-Purkinje conduction in the intact neonatal heart--characterization and amplification by N-acetylprocainamide. The Journal of pharmacology and experimental therapeutics. 1991 Nov; 259(2):535-42. doi: NULL. [PMID: 1719192]
  • J D Coyle, H Boudoulas, J J Lima. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype. Biopharmaceutics & drug disposition. 1991 Nov; 12(8):599-612. doi: 10.1002/bdd.2510120806. [PMID: 1724922]
  • E vasBinder, T Annesley. Liquid chromatographic analysis of mexiletine in serum, with alternate application to tocainide, procainamide, and N-acetylprocainamide. Biomedical chromatography : BMC. 1991 Jan; 5(1):19-22. doi: 10.1002/bmc.1130050106. [PMID: 1709575]
  • X D Liu, N Deng, S K Huang. [Simultaneous predictions of disposition kinetics of procainamide and its metabolite N-acetylprocainamide in rat by a physiological pharmacokinetic model]. Yao xue xue bao = Acta pharmaceutica Sinica. 1991; 26(10):725-32. doi: NULL. [PMID: 1726674]
  • T Dise, A Stolfi, S Yamasaki, A S Pickoff. Electropharmacodynamics of N-acetylprocainamide in the immature mammalian heart--evidence for a prominent class III effect in the newborn. Journal of cardiovascular pharmacology. 1991 Jan; 17(1):96-101. doi: 10.1097/00005344-199101000-00014. [PMID: 1708063]
  • W Sinkiewicz, A Marzec, A Jankowski, A Hoffmann, K Makuch, B Romański. [Verification of therapeutic levels of procainamide and N-acetyl- procainamide in ventricular arrhythmia]. Polski tygodnik lekarski (Warsaw, Poland : 1960). 1990 Jun; 45(23-24):458-60. doi: NULL. [PMID: 1703654]
  • C Funck-Brentano, R T Light, M D Lineberry, G M Wright, D M Roden, R L Woosley. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. Journal of cardiovascular pharmacology. 1989 Sep; 14(3):364-73. doi: 10.1097/00005344-198909000-00003. [PMID: 2476614]
  • A Fujimura, H Kajiyama, Y Kumagai, H Nakashima, K Sugimoto, A Ebihara. Chronopharmacokinetic studies of pranoprofen and procainamide. Journal of clinical pharmacology. 1989 Sep; 29(9):786-90. doi: 10.1002/j.1552-4604.1989.tb03420.x. [PMID: 2478591]
  • A J Atkinson, T I Ruo, A A Piergies, H C Breiter, T J Connelly, G S Sedek, D Juan, G L Hubler, A M Hsieh. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method. Clinical pharmacology and therapeutics. 1989 Aug; 46(2):182-9. doi: 10.1038/clpt.1989.124. [PMID: 2474402]
  • P H Vlasses, T Kosoglou, S L Chase, A J Greenspon, S Lottes, E Andress, R K Ferguson, M L Rocci. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. Archives of internal medicine. 1989 Jun; 149(6):1350-3. doi: NULL. [PMID: 2471472]
  • L A Bauer, D Black, A Gensler, J Sprinkle. Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations. International journal of clinical pharmacology, therapy, and toxicology. 1989 May; 27(5):213-6. doi: . [PMID: 2472362]
  • D S Echt, J N Black, J T Barbey, D R Coxe, E Cato. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. Circulation. 1989 May; 79(5):1106-17. doi: 10.1161/01.cir.79.5.1106. [PMID: 2469545]
  • M L Rocci, T Kosoglou, R K Ferguson, P H Vlasses. Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. The Journal of pharmacology and experimental therapeutics. 1989 Mar; 248(3):923-8. doi: NULL. [PMID: 2467982]
  • T Furukawa, H Herscovici, T Desai, R Sampsell, A Nogami, K Moroe, J J Rozanski, J W Lister. Rapid assessment of rate and antiarrhythmic drug effect on the myocardium using asymmetric biphasic pulse stimulation. Pacing and clinical electrophysiology : PACE. 1989 Jan; 12(1 Pt 1):52-64. doi: 10.1111/pace.1989.12.p1.52. [PMID: 2464811]
  • T Kosoglou, M L Rocci, P H Vlasses. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Clinical pharmacology and therapeutics. 1988 Oct; 44(4):467-77. doi: 10.1038/clpt.1988.181. [PMID: 2458879]
  • T Furukawa, K Taniguchi, J Takeuchi. The use of evoked endocardial response for assessment of antiarrhythmic drug effects on myocardium. The Bulletin of Tokyo Medical and Dental University. 1988 Sep; 35(3):33-44. doi: NULL. [PMID: 2466578]
  • A J Atkinson, T I Ruo, A A Piergies. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. Angiology. 1988 Jul; 39(7 Pt 2):655-67. doi: . [PMID: 2457345]
  • D E Hilleman, A J Patterson, S M Mohiuddin, B G Ortmeier, C J Destache. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias. Drug intelligence & clinical pharmacy. 1988 Jul; 22(7-8):554-8. doi: 10.1177/106002808802200706. [PMID: 2458219]
  • K Arimori, M Nakano. Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. Journal of pharmacobio-dynamics. 1988 Jul; 11(7):504-11. doi: 10.1248/bpb1978.11.504. [PMID: 2460613]
  • S Q Zhang, G C Olugo-Edege, Y P Zhu, F F Mao, D K An. [High performance liquid chromatographic method for determination of procainamide and its active metabolites, N-acetylprocainamide in serum]. Yao xue xue bao = Acta pharmaceutica Sinica. 1988 Jun; 23(6):430-4. doi: NULL. [PMID: 2463733]
  • P R Henry, R A Dhruv. More-sensitive enzyme-multiplied immunoassay technique for procainamide and N-acetylprocainamide in plasma, serum, and urine. Clinical chemistry. 1988 May; 34(5):957-60. doi: NULL. [PMID: 2453309]
  • D A Sica, C Yonce, R Small, E Cefali, A Harford, W Poynor. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. International journal of clinical pharmacology, therapy, and toxicology. 1988 Feb; 26(2):59-64. doi: NULL. [PMID: 2457560]
  • F Jamali, R S Alballa, R Mehvar, C H Lemko. Longer plasma half-life for procainamide utilizing a very sensitive high performance liquid chromatography assay. Therapeutic drug monitoring. 1988; 10(1):91-6. doi: 10.1097/00007691-198810010-00016. [PMID: 2453956]
  • K A Rodvold, F P Paloucek, D Jung, J Gallastegui. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine. Therapeutic drug monitoring. 1987 Dec; 9(4):378-83. doi: 10.1097/00007691-198712000-00003. [PMID: 2447687]
  • M Boucher, C Dubray, M Paire, P Duchêne-Marullaz. Comparative effects of procainamide and its N-acetylated metabolite in conscious dogs with atrioventricular block: plasma concentration-response relationships. Journal of cardiovascular pharmacology. 1987 Nov; 10(5):562-7. doi: 10.1097/00005344-198711000-00011. [PMID: 2447406]
  • J Watanabe, I Koyama, K Iwamoto, S Ozeki. Mandibular and parotid salivary excretion of procainamide and N-acetylprocainamide after intravenous administration of procainamide to rats. The Journal of pharmacy and pharmacology. 1987 Nov; 39(11):912-6. doi: 10.1111/j.2042-7158.1987.tb03128.x. [PMID: 2448449]
  • A A Piergies, T I Ruo, E M Jansyn, S M Belknap, A J Atkinson. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. Clinical pharmacology and therapeutics. 1987 Jul; 42(1):107-12. doi: 10.1038/clpt.1987.117. [PMID: 2439251]
  • M L Rocci, P Mojaverian, R J Davis, R K Ferguson, P H Vlasses. Food-induced gastric retention and absorption of sustained-release procainamide. Clinical pharmacology and therapeutics. 1987 Jul; 42(1):45-9. doi: 10.1038/clpt.1987.106. [PMID: 2439252]
  • K Okumura, A L Waldo. Effects of N-acetylprocainamide on experimental atrial flutter and atrial electrophysiologic properties in conscious dogs with sterile pericarditis: comparison with the effects of quinidine. Journal of the American College of Cardiology. 1987 Jun; 9(6):1332-8. doi: 10.1016/s0735-1097(87)80474-6. [PMID: 2438320]
  • J D Coyle, J J MacKichan, H Boudoulas, J J Lima. Reversed-phase liquid chromatography method for measurement of procainamide and three metabolites in serum and urine: percent of dose excreted as deethyl metabolites. Journal of pharmaceutical sciences. 1987 May; 76(5):402-5. doi: 10.1002/jps.2600760513. [PMID: 2443639]
  • M A Josephson, M Schwab, K Coyle, B N Singh. Effects of intravenous N-acetylprocainamide on hemodynamics and left ventricular function in man. American heart journal. 1987 Apr; 113(4):952-7. doi: 10.1016/0002-8703(87)90056-1. [PMID: 2436466]
  • D T Domoto, W W Brown, P Bruggensmith. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration. Annals of internal medicine. 1987 Apr; 106(4):550-2. doi: 10.7326/0003-4819-106-4-550. [PMID: 2435200]
  • A Yamaji, K Kataoka, M Oishi, N Kanamori, E Hiraoka, M Mishima. Simultaneous determination of procainamide and N-acetylprocainamide in serum by gas chromatography with nitrogen-selective detection. Journal of chromatography. 1987 Mar; 415(1):143-7. doi: 10.1016/s0378-4347(00)83202-8. [PMID: 2438294]
  • F Morady, L A DiCarlo, M de Buitleir, R B Krol, J M Baerman, W H Kou. Effects of incremental doses of procainamide on ventricular refractoriness, intraventricular conduction, and induction of ventricular tachycardia. Circulation. 1986 Dec; 74(6):1355-64. doi: 10.1161/01.cir.74.6.1355. [PMID: 2430731]
  • A J Atkinson, T I Ruo. Pharmacokinetics of N-acetylprocainamide. Angiology. 1986 Dec; 37(12 Pt 2):959-67. doi: NULL. [PMID: 2433970]
  • J Somberg, J Wynn, D Miura, V Torres, S Williams, D Keefe. N-acetylprocainamide's antiarrhythmic action in patients with ventricular tachycardia. Angiology. 1986 Dec; 37(12 Pt 2):972-81. doi: NULL. [PMID: 2433972]
  • M G Papich, L E Davis, C A Davis, B C McKiernan, S A Brown. Pharmacokinetics of procainamide hydrochloride in dogs. American journal of veterinary research. 1986 Nov; 47(11):2351-8. doi: NULL. [PMID: 2431636]
  • J J Lertora, L W King. Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. The Journal of pharmacology and experimental therapeutics. 1986 Sep; 238(3):893-9. doi: NULL. [PMID: 2427689]
  • D J Silberstein, C J Bowmer, M S Yates, H G Dean. Effect of acute renal failure on the disposition and elimination of [3H]N-acetyl procainamide ethobromide in the rat. The Journal of pharmacy and pharmacology. 1986 Sep; 38(9):679-85. doi: 10.1111/j.2042-7158.1986.tb03109.x. [PMID: 2430089]
  • D M Roden, K A Thompson, B F Hoffman, R L Woosley. Clinical features and basic mechanisms of quinidine-induced arrhythmias. Journal of the American College of Cardiology. 1986 Jul; 8(1 Suppl A):73A-78A. doi: 10.1016/s0735-1097(86)80032-8. [PMID: 2423573]
  • G L Braden, J P Fitzgibbons, M J Germain, H M Ledewitz. Hemoperfusion for treatment of N-acetylprocainamide intoxication. Annals of internal medicine. 1986 Jul; 105(1):64-5. doi: 10.7326/0003-4819-105-1-64. [PMID: 2424355]
  • S J Rosansky, M E Brady. Procainamide toxicity in a patient with acute renal failure. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1986 Jun; 7(6):502-6. doi: 10.1016/s0272-6386(86)80192-5. [PMID: 2424305]
  • T Annesley, K Matz, R Davenport, D Giacherio. A high performance liquid chromatographic assay for tocainide with alternate application for the determination of lidocaine, procainamide, and N-acetylprocainamide. Research communications in chemical pathology and pharmacology. 1986 Feb; 51(2):173-81. doi: . [PMID: 2421377]
  • P H Vlasses, R K Ferguson, M L Rocci, R M Raja, R S Porter, A M Greenspan. Lethal accumulation of procainamide metabolite in severe renal insufficiency. American journal of nephrology. 1986; 6(2):112-6. doi: 10.1159/000167065. [PMID: 2422935]
  • D Raphanaud, M Borensztejn, J P Dupeyron, F Guyon. High performance liquid chromatography of procainamide and N-acetylprocainamide in human blood plasma. Therapeutic drug monitoring. 1986; 8(3):365-7. doi: 10.1097/00007691-198609000-00023. [PMID: 2428144]
  • C L Raehl, A V Moorthy, G J Beirne. Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. Nephron. 1986; 44(3):191-4. doi: 10.1159/000183984. [PMID: 2431330]
  • J Wynn, D S Miura, V Torres, D Flowers, D Keefe, S Williams, J C Somberg. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. The American journal of cardiology. 1985 Nov; 56(13):877-81. doi: 10.1016/0002-9149(85)90774-x. [PMID: 2414983]
  • C L Raehl, A K Patel, M LeRoy. Drug-induced torsade de pointes. Clinical pharmacy. 1985 Nov; 4(6):675-90. doi: . [PMID: 2416504]
  • B Bruguerolle, G Jadot. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat. The Journal of pharmacy and pharmacology. 1985 Sep; 37(9):654-6. doi: 10.1111/j.2042-7158.1985.tb05105.x. [PMID: 2416904]
  • W G Stevenson, J Weiss. Torsades de pointes due to n-acetylprocainamide. Pacing and clinical electrophysiology : PACE. 1985 Jul; 8(4):528-31. doi: 10.1111/j.1540-8159.1985.tb05854.x. [PMID: 2410877]
  • D Jung, M Nanavaty, P Prasad. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition. Drug metabolism and disposition: the biological fate of chemicals. 1985 May; 13(3):359-63. doi: NULL. [PMID: 2410212]
  • J D Coyle, H Boudoulas, J J Mackichan, J J Lima. Concentration-dependent clearance of procainamide in normal subjects. Biopharmaceutics & drug disposition. 1985 Apr; 6(2):159-65. doi: 10.1002/bdd.2510060207. [PMID: 2408690]
  • T M Ludden, M H Crawford, G T Kennedy. N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias. Pharmacotherapy. 1985 Jan; 5(1):11-5. doi: 10.1002/j.1875-9114.1985.tb04450.x. [PMID: 2580291]
  • F E Marchlinski, A E Buxton, J A Vassallo, H L Waxman, D M Cassidy, J U Doherty, M E Josephson. Comparative electrophysiologic effects of intravenous and oral procainamide in patients with sustained ventricular arrhythmias. Journal of the American College of Cardiology. 1984 Dec; 4(6):1247-54. doi: 10.1016/s0735-1097(84)80145-x. [PMID: 6209319]
  • G P Sanna. New drugs in the management of ventricular arrhythmias. Giornale italiano di cardiologia. 1984 Oct; 14(10):788-97. doi: . [PMID: 6083894]
  • M J Chow, A A Piergies, D J Bowsher, J J Murphy, W Kushner, T I Ruo, A Asada, J V Talano, A J Atkinson. Torsade de pointes induced by N-acetylprocainamide. Journal of the American College of Cardiology. 1984 Sep; 4(3):621-4. doi: 10.1016/s0735-1097(84)80111-4. [PMID: 6206104]
  • C D Christian, C G Meredith, K V Speeg. Cimetidine inhibits renal procainamide clearance. Clinical pharmacology and therapeutics. 1984 Aug; 36(2):221-7. doi: 10.1038/clpt.1984.166. [PMID: 6204803]
  • P D Kroboth, K Mitchum, J B Puschett. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1984 Jul; 4(1):78-9. doi: 10.1016/s0272-6386(84)80032-3. [PMID: 6204527]
  • E G Giardina. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias. Annals of the New York Academy of Sciences. 1984; 432(?):177-88. doi: 10.1111/j.1749-6632.1984.tb14519.x. [PMID: 6084435]
  • R Raja, M Kramer, R Alvis, S Goldstein, A DeLosAngeles. Resin hemoperfusion for severe N-acetylprocainamide toxicity in patients with renal failure. Transactions - American Society for Artificial Internal Organs. 1984; 30(?):18-20. doi: NULL. [PMID: 6085435]
  • B Kark, N Sistovaris, A Keller. Thin-layer chromatographic determination of procainamide and N-acetylprocainamide in human serum and urine at single-dose levels. Journal of chromatography. 1983 Oct; 277(?):261-72. doi: 10.1016/s0378-4347(00)84843-4. [PMID: 6196373]
  • R L Woosley, D M Roden. Importance of metabolites in antiarrhythmic therapy. The American journal of cardiology. 1983 Sep; 52(6):3C-7C. doi: 10.1016/0002-9149(83)90625-2. [PMID: 6194679]
  • P B Christoff, D R Conti, C Naylor, W J Jusko. Procainamide disposition in obesity. Drug intelligence & clinical pharmacy. 1983 Jul; 17(7-8):516-22. doi: 10.1177/106002808301700704. [PMID: 6191939]
  • A Yacobi, B L Kamath, H F Stampfli, Z M Look, C M Lai. Age-related pharmacokinetics of N-acetylprocainamide in rats. Journal of pharmaceutical sciences. 1983 Jul; 72(7):789-92. doi: 10.1002/jps.2600720718. [PMID: 6193264]
  • C P Patel. Improved liquid chromatographic determination of procainamide and N-acetylprocainamide in serum. Therapeutic drug monitoring. 1983 Jun; 5(2):235-8. doi: 10.1097/00007691-198306000-00016. [PMID: 6192559]
  • A J Atkinson, J J Lertora, W Kushner, G C Chao, M J Nevin. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. Clinical pharmacology and therapeutics. 1983 May; 33(5):565-76. doi: 10.1038/clpt.1983.77. [PMID: 6188570]
  • R J Sung, Z Juma, S Saksena. Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias. American heart journal. 1983 May; 105(5):811-9. doi: 10.1016/0002-8703(83)90245-4. [PMID: 6189384]
  • A Somogyi, A McLean, B Heinzow. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. European journal of clinical pharmacology. 1983; 25(3):339-45. doi: 10.1007/bf01037945. [PMID: 6194997]
  • M J Zema, T Mirando. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation. Angiology. 1983 Jan; 34(1):32-9. doi: 10.1177/000331978303400104. [PMID: 6186164]
  • P Ylitalo, R Ruosteenoja, O Leskinen, T Metsä-Ketelä. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide. European journal of clinical pharmacology. 1983; 25(6):791-5. doi: 10.1007/bf00542522. [PMID: 6198178]
  • A Somogyi, B Heinzow. Cimetidine reduces procainamide elimination. The New England journal of medicine. 1982 Oct; 307(17):1080. doi: 10.1056/nejm198210213071715. [PMID: 6181402]
  • C N Ou, V L Frawley. Theophylline, dyphylline, caffeine, acetaminophen, salicylate, acetylsalicylate, procainamide, and N-acetylprocainamide determined in serum with a single liquid-chromatographic assay. Clinical chemistry. 1982 Oct; 28(10):2157-60. doi: . [PMID: 6181911]
  • J H Rodman, A Hurst, T Gaarder, J Cohen, R W Jelliffe. N-Acetylprocainamide kinetics and clinical response during repeated dosing. Clinical pharmacology and therapeutics. 1982 Sep; 32(3):378-86. doi: 10.1038/clpt.1982.175. [PMID: 6179685]
  • P J Basseches, G J DiGregorio. Excretion of procainamide into bile and saliva in rats with chronic renal failure. Archives internationales de pharmacodynamie et de therapie. 1982 Jun; 257(2):180-7. doi: NULL. [PMID: 6180690]
  • T D McKinney, K V Speeg. Cimetidine and procainamide secretion by proximal tubules in vitro. The American journal of physiology. 1982 Jun; 242(6):F672-80. doi: 10.1152/ajprenal.1982.242.6.f672. [PMID: 6178296]
  • S J Connolly, R E Kates. Clinical pharmacokinetics of N-acetylprocainamide. Clinical pharmacokinetics. 1982 May; 7(3):206-20. doi: 10.2165/00003088-198207030-00002. [PMID: 6178545]
  • K M Kessler, P Ho-Tung, B Steele, J Silver, A Pickoff, S Narayanan, R J Myerburg. Simultaneous quantitation of quinidine, procainamide, and N-acetylprocainamide in serum by gas-liquid chromatography with a nitrogen-phosphorus selective detector. Clinical chemistry. 1982 May; 28(5):1187-90. doi: 10.1093/clinchem/28.5.1187. [PMID: 6176367]
  • T M Ludden, M H Crawford. N-Acetylprocainamide kinetics after single and repeated oral doses. Clinical pharmacology and therapeutics. 1982 Mar; 31(3):343-9. doi: 10.1038/clpt.1982.44. [PMID: 6174262]
  • R H Tannen, S Cunningham-Rundles. Inhibition of Con A mitogenesis by serum from procainamide-treated patients and patients with systemic lupus erythematosus. Immunological communications. 1982; 11(1):33-45. doi: 10.3109/08820138209050722. [PMID: 6178682]